Samantha DiGrande

Articles by Samantha DiGrande

From the Oncology Care Model to the possibilities of cannabis, policy issues drew big crowds at the 2019 Annual Meeting of the American Society of Clinical Oncology.

Early detection and treatment of lung cancer through screening with low-dose computed tomography (CT) has been investigated as a potential tool for reducing lung cancer deaths, the leading cause of cancer death worldwide, for more than 2 decades. Published this week was an extended follow up study to the 2011 randomized National Lung Screening Trial that found a similar number of patients must be screened to prevent cancer deaths as determined in the original analysis.

In a session held during the Florida Society of Clinical Oncology’s annual meeting in April, panelist James Almas, MD, vice president and national medical director of clinical effectiveness at LabCorp, and previously a medical officer at CMS in the Coverage Analysis Group, announced that he expected the National Coverage Determination to be reopened for Foundation Medicine’s FDA-approved companion diagnostic. By the end of the month, CMS revealed that they had done just that.

Impulsive and compulsive behaviors have become increasingly associated with Parkinson disease (PD) and treatment. Recently, the International Parkinson’s and Movement Disorder Society commissioned a task force to assess currently available screening tools and rating scales in order to make recommendations regarding their utility, as well as to inform future directions in scale development and validation.

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

According to results from a randomized phase 3 trial presented at the American Society of Clinical Oncology’s recent annual meeting, the addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improvement progression-free survival (PFS) and the overall response rate (ORR) in patients with relapsed or refractory multiple myeloma (RRMM).



Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo